New vaccine targets group b strep in seniors
NCT ID NCT05782179
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This study tested a new vaccine against Group B Streptococcus bacteria in 90 healthy adults aged 55 to 75. Participants received three doses of the vaccine or a placebo and were monitored for safety and immune response for 6 months. The goal was to see if the vaccine is safe and helps the body build defenses against this infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCAL INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department
Ghent, 9000, Belgium
Conditions
Explore the condition pages connected to this study.